Takeda Pharmaceuticals Australia has notified us that due to the increase in demand for other strengths, Vyvanse (lisdexamfetamine dimesilate) 40 mg will be in shortage in Australia from 22 January 2024 until 30 April 2024.
The current anticipated return-to-supply dates for the different strengths of Vyvanse are published on the Medicine Shortage Reports Database.
We have approved the supply of overseas-registered alternatives to Vyvanse 30 mg, 50 mg and 60 mg under section 19A of the Therapeutic Goods Act 1989. Up-to-date information about these products is available on the Section 19A approvals database.
